On the evening of March 27, Giant Biogene Holding (HK:02367), a professional skincare company, released its first financial report since going public. In the 2022 fiscal year, the company’s sales revenue increased by 52.3% year-on-year to RMB 2.3644 billion, and net profit attributable to shareholders increased by 21% year-on-year to RMB 1.002 billion.
After the financial report was released, Giant Biogene’s stock price fell by 8.89% to HKD 47.65 on March 28th. Since its IPO, the company’s stock price has accumulated an 83.27% increase, and its current market value i …
